A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants
Latest Information Update: 18 Feb 2026
At a glance
- Drugs LWP 779 (Primary)
- Indications Ischaemic stroke
- Focus Adverse reactions
- Sponsors Longwood Biopharma
Most Recent Events
- 18 Feb 2026 New trial record